These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 28498452

  • 1. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Liu L, Lou N, Li X, Xu G, Ruan H, Xiao W, Qiu B, Bao L, Yuan C, Huang X, Wang K, Cao Q, Chen K, Yang H, Zhang X.
    Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
    [Abstract] [Full Text] [Related]

  • 2. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
    Moon SJ, Jeong BC, Kim HJ, Lim JE, Kim HJ, Kwon GY, Jackman JA, Kim JH.
    Theranostics; 2021 Jun; 11(2):958-973. PubMed ID: 33391515
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH, Ku JY, Ha JM, Bae SS, Lee JZ, Kim CS, Ha HK.
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [Abstract] [Full Text] [Related]

  • 8. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
    McGrath MJ, Binge LC, Sriratana A, Wang H, Robinson PA, Pook D, Fedele CG, Brown S, Dyson JM, Cottle DL, Cowling BS, Niranjan B, Risbridger GP, Mitchell CA.
    Cancer Res; 2013 Aug 15; 73(16):5066-79. PubMed ID: 23801747
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.
    Zhang G, Liu X, Li J, Ledet E, Alvarez X, Qi Y, Fu X, Sartor O, Dong Y, Zhang H.
    Oncotarget; 2015 Sep 15; 6(27):23358-71. PubMed ID: 26160840
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
    Chen Z, Wu D, Thomas-Ahner JM, Lu C, Zhao P, Zhang Q, Geraghty C, Yan PS, Hankey W, Sunkel B, Cheng X, Antonarakis ES, Wang QE, Liu Z, Huang TH, Jin VX, Clinton SK, Luo J, Huang J, Wang Q.
    Proc Natl Acad Sci U S A; 2018 Jun 26; 115(26):6810-6815. PubMed ID: 29844167
    [Abstract] [Full Text] [Related]

  • 14. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
    Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G, Riisnaes R, Uo T, Neeb A, Welti J, Morrissey C, Carreira S, Luo J, Nelson PS, Balk SP, True LD, de Bono JS, Plymate SR.
    J Clin Invest; 2019 Jan 02; 129(1):192-208. PubMed ID: 30334814
    [Abstract] [Full Text] [Related]

  • 15. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
    Kohli M, Ho Y, Hillman DW, Van Etten JL, Henzler C, Yang R, Sperger JM, Li Y, Tseng E, Hon T, Clark T, Tan W, Carlson RE, Wang L, Sicotte H, Thai H, Jimenez R, Huang H, Vedell PT, Eckloff BW, Quevedo JF, Pitot HC, Costello BA, Jen J, Wieben ED, Silverstein KAT, Lang JM, Wang L, Dehm SM.
    Clin Cancer Res; 2017 Aug 15; 23(16):4704-4715. PubMed ID: 28473535
    [Abstract] [Full Text] [Related]

  • 16. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT.
    Oncogene; 2020 Nov 15; 39(45):6935-6949. PubMed ID: 32989253
    [Abstract] [Full Text] [Related]

  • 17. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment.
    Kregel S, Wang C, Han X, Xiao L, Fernandez-Salas E, Bawa P, McCollum BL, Wilder-Romans K, Apel IJ, Cao X, Speers C, Wang S, Chinnaiyan AM.
    Neoplasia; 2020 Feb 15; 22(2):111-119. PubMed ID: 31931431
    [Abstract] [Full Text] [Related]

  • 18. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel EA, Nelson PS, Taplin ME, Balk SP, Cai C.
    Clin Cancer Res; 2016 Jul 15; 22(14):3672-82. PubMed ID: 26936914
    [Abstract] [Full Text] [Related]

  • 19. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ, Milowsky MI, Whang YE.
    Clin Pharmacol Ther; 2015 Dec 15; 98(6):582-9. PubMed ID: 26331358
    [Abstract] [Full Text] [Related]

  • 20. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer].
    Chen ZY, Dong Q, Liu LR, Wei Q.
    Zhonghua Nan Ke Xue; 2019 Feb 15; 25(2):172-176. PubMed ID: 32216207
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.